Open AccessPB1773 OVERAL SURVIVAL OF MEXICAN NATIONAL REGISTRY OF ACUTE PROMYEOLOCYTIC LEUKEMIA, AN ANALYSIS OF 324 CASES
Author(s) -
Zapata N.,
Montaño E.,
Ramos C.,
Espinoza R.,
Solis J.C.,
Barrera E.,
Mijangos J.,
Diaz G.,
Solís R.,
Perez O.,
Herrera M.,
Gomez D.,
Cabrera A.,
Flores J.A.,
Solano M.,
Guillermo V.,
Ceballos A.,
Ojeda J.,
Gomez G.,
Lyn L.,
Mena V.,
De la Peña J.A.,
Ortiz M.,
Perez J.,
Espitia M.E.,
Alvarez J.L.,
Aguilar M.,
Alvarado M.
Publication year - 2019
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000565600.96747.37
Subject(s) - acute promyelocytic leukemia , medicine , myeloid leukemia , epidemiology , acute leukemia , leukemia , population , pediatrics , surgery , biochemistry , retinoic acid , chemistry , environmental health , gene
Background: Acute Promyelocytic Leukemia is a myeloid dissease wich is informed to be more frequent in latinos, but there is few epidemiological data about these. This is a review of 19 Hospitals in different states of Mexico, from Northern to South of Mexico. A retrospective study of all cases of acute promyelocytic leukemia treated from 2007‐2018, a total of 324 cases. Aims: Our Aim objective is to know our overall survival of the population with acute promyelocyic leukemia treated in different institutions in Mexico Secondary objectives: Learn about treatment used in theses different institutions, and mortality related. Methods: We perform a rtrospective analysis from 2007‐2018, a total of 324 cases diagnose with acute promylocytic leukemia, inform consent was perform in all cases Results: The Median age 36 years old (range 15‐73), relation male:female 163:161. Infection at diagnosis 12%(39cases), DIC 31% (102 cases), Hemorrages 21%, CNS:8cases, Gastrointestinal 18cases, urinary tract:15, skin:28 cases. Leucocite at diagnosis median of 22.3 (1.0‐450), Platelets median of 40 (2‐318), Fybrogen median 190 range22‐825, TTPa 32 seconds (28‐255). Risk at diagnosis: low 36%, intermediate:24%, high risk:40%. ATRA used in 94% of the cases and antracyclines used Daunorrubicin 58%, and Idarrubicin 42%. Mortality of 14%. ATRA syndrome 16% in the Daunorrubicin arm and 20% idarrubicin Summary/Conclusion: We show that patient treated with daunorrubicin had a better survival during the induction, with a overall mortality of 14% in the induction related mortality. Median age of diagnosis 36 years old. In Mexico there is no ATO, so we still treating patients with chemotherapy and a maintenance of 2 years afther 3 consolidations, the most used atracycline is daunorrubicin. There was no difference between the ATRA syndrome in both antracyclines.